Abiomed Expands Heart Recovery Biz With New Circulatory Support Console
This article was originally published in The Gray Sheet
Executive Summary
Abiomed is banking on its iPulse console, approved by FDA Dec. 18, to drive sales across its full acute cardiac assist portfolio and provide entrée into the $200 million intra-aortic balloon market
You may also be interested in...
New Products In Brief
New AneuRx delivery system: Medtronic launches Jan. 10 its AneurX AAAdvantage endovascular stent graft on a new delivery system called Xcelerant Hydro. Compared with the previous Xcelerant system with which AneuRx AAAdvantage launched in the U.S. in March 2006, Xcelerant Hydro has a hydrophilic coating to reduce friction and facilitate navigation of small and tortuous arteries. Medtronic completed a PMA submission for another abdominal aortic aneurysm stent graft, Talent Abdominal, in November (1"The Gray Sheet" Dec. 10, 2007, p. 6). That device's delivery system is called CoilTrac
New Products In Brief
New AneuRx delivery system: Medtronic launches Jan. 10 its AneurX AAAdvantage endovascular stent graft on a new delivery system called Xcelerant Hydro. Compared with the previous Xcelerant system with which AneuRx AAAdvantage launched in the U.S. in March 2006, Xcelerant Hydro has a hydrophilic coating to reduce friction and facilitate navigation of small and tortuous arteries. Medtronic completed a PMA submission for another abdominal aortic aneurysm stent graft, Talent Abdominal, in November (1"The Gray Sheet" Dec. 10, 2007, p. 6). That device's delivery system is called CoilTrac
Abiomed Invests In Long-Term LVAD Support With WorldHeart
Abiomed is diversifying its ventricular assist device holdings with a $5 million strategic investment in WorldHeart, announced Dec. 12